Intraabdominal HypertensionNCT06221293
Correlation Between Intra-abdominal Pressure, Biomarkers of Bacterial Translocation and Intestinal Wall Damage
An observational study of Intraabdominal Hypertension and Multi-Organ Disorder, run by Karaganda Medical University at 5 sites in Kazakhstan.
Trial summary
Main scientific hypotheses of the project: 1. The level of intestinal microflora translocation markers and biomarkers of intestinal wall damage the in the blood serum correlates with the level of intra-abdominal pressure, regardless of the genesis of intra-abdominal hypertension. 2. Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Intraabdominal Hypertension, Multi-Organ Disorder, Translocation Syndrome
- What is being tested?
- immunoenzyme analysis
- How many people
- 180 participants
- Where
- 5 sitesKazakhstan
- Study dates
- 1 Mar 2023to 27 Dec 2025
- How long will I take part?
- 10 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients over 18 years of age with multi-organ dysfunction syndrome and increased intra-abdominal pressure
Who may be able to join
- registered multiple organ dysfunction syndrome of various genesis
- over 18 years of age.
Who cannot join
- age under 18
- pregnancy
- HIV infection
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Kazakhstan5 sites
Karaganda Medical University
Karaganda, 1000000
Clinic of the Medical University of Karaganda
Karaganda, 100000
Multidisciplinary hospital No. 1
Karaganda, 100000
Multidisciplinary Hospital No. 3
Karaganda, 100000
Regional Clinic Hospital
Karaganda, 100000
About this study
Official title: Study of the Relationship Between Intra-abdominal Pressure, Biomarkers of Bacterial Translocation and Intestinal Wall Damage in Multiple Organ Dysfunction Syndrome.
Main scientific hypotheses of the project:
- The level of intestinal microflora translocation markers and biomarkers of intestinal wall damage the in the blood serum correlates with the level of intra-abdominal pressure, regardless of the genesis of intra-abdominal hypertension.
- The critical levels of intestinal microflora translocation markers and biomarkers of the intestinal wall damage can be used for predicting an unfavorable outcome in the multiple organ dysfunction syndrome.
- The revealed critical level of intra-abdominal pressure is an additional prognostic sign in assessing the course of the multiple organ dysfunction syndrome.
Read more
. Project objectives:
- To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.
- To identify differences in the level of markers of bacterial translocation of the intestinal microflora and the level of markers of the intestinal wall damage in patients with intra-abdominal hypertension. In patients with multiple organ dysfunction syndrome, the levels of biomarkers of bacterial translocation of the intestinal microflora and biomarkers of intestinal wall damage in the blood serum correlate with intra-abdominal pressure indicators, regardless of the etiology of intra-abdominal hypertension.
- Assess the impact of the level of intra-abdominal pressure on the development and course of the syndrome of multiple organ dysfunction. To assess the course of the syndrome of multiple organ dysfunction, an additional prognostic marker is the determination of the critical level of intra-abdominal pressure.
- Determine the critical levels of biomarkers of intestinal microflora translocation and biomarkers of intestinal wall damage to predict the outcome of diseases accompanied by the development of multiple organ dysfunction syndrome. The obtained critical levels of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage will be significant indicators in the syndrome of multiple organ dysfunction for predicting an unfavorable outcome.
Read the detailed description
The aim of the project is to evaluate the impact of intra-abdominal hypertension, biomarkers of bacterial translocation and biomarkers of intestinal wall damage on the course and outcomes of the disease in patients with multiple organ dysfunction.
Today the intestinal microflora translocation is considered as one of the key mechanism of an enhanced systemic inflammatory response that leads to multiple organ dysfunction. In the intensive care unit, in patients in serious condition changes in various body systems develop, including the immune system reacts with the production of endogenous pro-inflammatory mediators, and due to microcirculation disorders, ischemia and hypoxia of the intestinal wall, aggravated by an increase in intra-abdominal pressure, its permeability increases, its barrier function is impaired. As a result, bacteria and/or their endotoxins penetrate the damaged intestinal barrier and further enhance the immune response, which becomes systemic and ultimately leads to multiple organ dysfunction. When the described processes occur, the assessment of splanchnic blood flow becomes especially relevant.
sCD14-ST (presepsin) and LBP (lipopolysaccharide-binding protein) are being studied as biomarkers of bacterial translocation, and I-FABP (Intestinal fatty-acid binding protein), REG3α (regenerating islet-derived protein-3α) and Zonulin (zonulin) are being studied as biomarkers of intestinal wall injury.
The interaction of the macrophage membrane protein CD14 with peptidoglycans of gram-positive and lipopolysaccharides of the walls of gram-negative bacteria leads to the production of sCD14-ST. Presepsin is a biomarker for the early phase of sepsis and a predictor of outcome in septic patients.
LBP increases the sensitization of receptors of cells of the immune system: macrophages, monocytes, neutrophils to bacterial lipopolysaccharide, which leads to the activation of the immune response by releasing pro-inflammatory mediators. LBP appears to be an effective biomarker for bacterial translocation and the development of septic complications.
I-FABP is a protein that is located on the villi of mature enterocytes. An increase in the level of I-FABP in the blood serum is associated with a violation of the permeability of the intestinal wall, which has been proven in a number of studies.
Paneth cells secrete the antimicrobial protein REG3α into the intestine, and in case of the intestinal wall damage, it moves into the bloodstream. This protein is a reliable biomarker of intestinal wall damage.
Zonulin is a protein that playing a significant role in intestinal wall permeability. It opens the intracellular tight junctions between the cells of the duodenum and small intestine, which leads to an increase in the permeability of the intestinal wall. Therefore, serum zonulin is a marker of dysfunction and increased permeability of the intestinal barrier.
In the databases of publications (Scopus, Web of Science) there were no articles on the study of the relationship between the level of biomarkers of intestinal translocation, the level of biomarkers of the intestinal wall damage and the level of intra-abdominal pressure in patients with multiple organ dysfunction syndrome. This study will allow a more in-depth study of the pathogenesis of intestinal microflora translocation in patients with multiple organ dysfunction syndrome, and will also allow using the results obtained to predict the course of this condition.
Detection of blood serum biomarkers sCD14-ST, LBP, I-FABP, REG3α and Zonulin will be performed by enzyme immunoassay. The level of intra-abdominal pressure will be measured by the method of tonometry in the bladder through a urethral catheter using a portable invasive low pressure meter (IIND - 500/75) by Triton-Electronics LLC.
The expected scientific results of studying the relationship between intra-abdominal pressure, the phenomenon of translocation of intestinal microflora into the systemic circulation with the pathogenesis and dynamics of the development of multiple organ dysfunction syndrome will have an impact on the further improvement of the treatment tactics of this pathology. Innovative methods for diagnosing the phenomenon of intestinal microflora translocation will have a positive effect on the development of laboratory diagnostics and science in Kazakhstan.
Revealing of relationships between intestinal microflora translocation biomarkers, biomarkers of the intestinal wall damage and changes in intra-abdominal pressure will allow a more in-depth study of the pathogenetic mechanisms in the development and course of the multiple organ dysfunction syndrome, depending on its genesis, which will allow using the results obtained to predict the outcomes of this syndrome.
2.2. The aim of the project is to evaluate the impact of intra-abdominal hypertension, biomarkers of bacterial translocation, and biomarkers of the intestinal wall damage on the course and outcomes of the disease in patients with multiple organ dysfunction.
2.3. Project objectives:
- To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.
- To identify differences in the level of markers of bacterial translocation of the intestinal microflora and the level of markers of the intestinal wall damage in patients with intra-abdominal hypertension. In patients with multiple organ dysfunction syndrome, the levels of biomarkers of bacterial translocation of the intestinal microflora and biomarkers of intestinal wall damage in the blood serum correlate with intra-abdominal pressure indicators, regardless of the etiology of intra-abdominal hypertension.
- Assess the impact of the level of intra-abdominal pressure on the development and course of the syndrome of multiple organ dysfunction. To assess the course of the syndrome of multiple organ dysfunction, an additional prognostic marker is the determination of the critical level of intra-abdominal pressure.
- Determine the critical levels of biomarkers of intestinal microflora translocation and biomarkers of intestinal wall damage to predict the outcome of diseases accompanied by the development of multiple organ dysfunction syndrome. The obtained critical levels of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage will be significant indicators in the syndrome of multiple organ dysfunction for predicting an unfavorable outcome.
- Scientific novelty and significance of the project Multiple Organ Dysfunction Syndrome (MODS) is a potentially reversible physiological disorder involving two or more organ systems not involved in the process resulting in intensive care unit (ICU) hospitalization. MODS results in longer ICU stays and, in severe cases, leads to high mortality (27%-100%).
In this scientific project, it is planned to study the levels of biomarkers of bacterial translocation (sCD14-ST, LBP) levels of biomarkers of intestinal wall damage (I-FABP, REG3α and Zonulin) and intra-abdominal pressure in patients with multiple organ dysfunction syndrome.
The interaction of the macrophage membrane protein CD14 with peptidoglycans of gram-positive and lipopolysaccharides of the walls of gram-negative bacteria leads to the production of sCD14-ST . Presepsin is a biomarker for the early phase of sepsis and a predictor of outcome in septic patients.
LBP increases the sensitization of receptors of cells of the immune system: macrophages, monocytes, neutrophils to bacterial lipopolysaccharide, which leads to the activation of the immune response by releasing pro-inflammatory mediators. LBP appears to be an effective biomarker for bacterial translocation and the development of septic complications.
I-FABP is a protein that is located on the villi of mature enterocytes. An increase in the level of I-FABP in the blood serum is associated with a violation of the permeability of the intestinal wall, which has been proven in a number of studies.
Paneth cells secrete the antimicrobial protein REG3α into the intestine, and in case of the intestinal wall damage, it moves into the bloodstream. This protein is a reliable biomarker of intestinal wall damage and bacterial translocation.
Zonulin first described like it is a protein that playing a significant role in intestinal wall permeability. It opens the intracellular tight junctions between the cells of the duodenum and small intestine, which leads to an increase in the permeability of the intestinal wall. Therefore, serum zonulin is a marker of dysfunction and increased permeability of the intestinal barrier.
- Research methods The type of research being conducted is fundamental research. The design of the study complies with the principles of the Declaration of Helsinki of the World Medical Association and was approved by the Local Commission on Bioethics of the NJSC KMU. Clinical bases in Karaganda, where biological material will be taken: Multidisciplinary Hospital No. 1, Regional Clinical Hospital, Clinic of Medical University. Laboratory research will be carried out on the basis of the Research Laboratory of the Institute of Life Sciences of the NJSC KMU.
Main scientific hypotheses of the project:
- The level of intestinal microflora translocation markers and biomarkers of intestinal wall damage the in the blood serum correlates with the level of intra-abdominal pressure, regardless of the genesis of intra-abdominal hypertension.
- The critical levels of intestinal microflora translocation markers and biomarkers of the intestinal wall damage can be used for predicting an unfavorable outcome in the multiple organ dysfunction syndrome.
- The revealed critical level of intra-abdominal pressure is an additional prognostic sign in assessing the course of the multiple organ dysfunction syndrome.
Research material. It is planned to study bacterial translocation biomarkers (sCD14-ST, LBP), biomarkers of intestinal wall damage (I-FABP, REG3α and Zonulin) in blood serum and measure intra-abdominal pressure in 180 patients with multiple organ dysfunction syndrome.
Measurement of intra-abdominal pressure will be carried out in patients with multiple organ dysfunction syndrome through a urethral catheter using a portable electronic device "ILPM - 500/75" (invasive low-pressure meter) manufactured by LLC "Triton - ElectronicS", Yekaterinburg, RF.
Technique for measuring intra-abdominal pressure: 50 ml of warm sterile isotonic sodium chloride solution is injected into the previously emptied bladder through a Foley catheter with an inflated balloon using a syringe without a needle. The urethral catheter is attached to the measuring device. With the valve of the urethral catheter closed, a zero value is set, after which the valve of the catheter is opened and the intra-abdominal pressure is recorded according to the indication on the display of the device
Risks and their solutions:
- With an increase in prices for the necessary reagents and materials due to the constant change in the exchange rate, most of the purchase will be carried out in the 1st year of the project implementation. Reducing the number of studies conducted while maintaining statistical significance without significant losses for the project.
- When changing the place and dates of congresses and conferences with a change in travel costs, there will be changes in the number of business travelers.
- Being tested
- immunoenzyme analysis
- Keywords
- bacterial translocation, presepsin, intraabdominal hypertension, multi-organ disorder, I-FABP, REG3a, Zonulin
- Medical subject headings
- Intra-Abdominal Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
immunoenzyme analysisDiagnostic test
immunoenzyme analysis with EVOLIS system
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | the first group consists of patients with increased abdominal pressure, signs of multi-organ failure with a fatal outcome Receives: Diagnostic Test: immunoenzyme analysis | |
| Group 2 | the second group consists of patients with increased abdominal pressure, signs of multi-organ failure without death Receives: Diagnostic Test: immunoenzyme analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection of biomarkers of translocation
To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.
Measured: 3-10 days
Secondary outcomes (1)
The differences between level of bacterial translocation and level of markers of the intestinal wall damage with intraabdominal hypertension
To identify differences in the level of markers of bacterial translocation of the intestinal microflora and the level of markers of the intestinal wall damage in patients with intra-abdominal hypertension. In patients with multiple organ dysfunction syndrome, the levels of biomarkers of bacterial translocation of the intestinal microflora and biomarkers of intestinal wall damage in the blood serum correlate with intra-abdominal pressure indicators, regardless of the etiology of intra-abdominal hypertension.
Measured: 3-10 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jan 2024
- Study start1 Mar 2023
- Primary completion25 Dec 2025 (estimated)
- Study completion27 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Intraabdominal HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Prospective
- Enrolment
- 180 participants (estimated)
- Target duration
- 10 Days
Sponsor and investigators
- Lead sponsor
- Karaganda Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Alina Ogizbaeva, dr, Principal investigator, young scientist, phDKairat Shakeyev, dr, Principal investigator, head of the surgical service of the CSE "Multidisciplinary Hospital No. 3 of KaragandaDmitry Matyushko, dr, Principal investigator, PhD, Associate Professor of the Department of Surgical DiseasesMiras Mugazov, dr, Principal investigator, PhD, Associate Professor of the Department of Emergency Medical CareDana Amanova, dr, Study chair, PhD, young scientist, co-investigatorZhibek Zhumadilova, Study chair, young scientist, co-investigatorShynggys Nuraly, Study chair, young scientist, co-investigatorSofiko Assamidanova, Study chair, young scientist, co-investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06221293
- Sponsor's protocol ID
- ИРН АР 19677271
- Other IDs
- ИРН AP19677271
- Status last verified
- Apr 2024
- First submitted
- 15 Jan 2024
- Last updated
- 19 Apr 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Turgunov Y, Ogizbayeva A, Akhmaltdinova L, Shakeyev K. Lipopolysaccharide-binding protein as a risk factor for development of infectious and inflammatory postsurgical complications in colorectal cancer paients. Contemp Oncol (Pozn). 2021;25(3):198-203. doi: 10.5114/wo.2021.110051. Epub 2021 Oct 14.
PubMed 34729040Shakeyev K, Turgunov Y, Ogizbayeva A, Avdiyenko O, Mugazov M, Grigolashvili S, Azizov I. Presepsin (soluble CD14 subtype) as a risk factor for the development of infectious and inflammatory complications in operated colorectal cancer patients. Ann Coloproctol. 2022 Dec;38(6):442-448. doi: 10.3393/ac.2022.00115.0016. Epub 2022 Apr 4.
PubMed 35368178Amanova DY, Lavrinenko AV, Kaliyeva DK, Matyushko DN, Ivachyov PA, Turgunov YM. Comparative Evaluation of Translocation of GFP Producing Escherichia coli Strains in Acute Intestinal Obstruction. Bull Exp Biol Med. 2019 Sep;167(5):660-662. doi: 10.1007/s10517-019-04593-y. Epub 2019 Oct 17.
PubMed 31625067Ivachyov P, Amanova D, Akhmaltdinova L, Koishibayev Z, Turgunov E. [COMPARISON OF DYNAMICS OF LEVEL OF PROCALCITONIN, LIPOPOLYSACCHARIDE BINDING PROTEIN AND INTERLEUKIN-6 IN BLOOD SERUM OF EXPERIMENTAL ANIMALS AT STRANGULATED AND OBTURATIVE INTESTINAL OBSTRUCTION]. Georgian Med News. 2020 Jun;(303):173-177. Russian.
PubMed 32841201
Study at a glance
From the registry record, last updated by the sponsor on 19 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Relationship Between Intra-abdominal Pressure, Biomarkers of Bacterial Translocation and Intestinal Wall Damage in Multiple Organ Dysfunction Syndrome.
- ClinicalTrials.gov ID
- NCT06221293
- Acronym / sponsor ID
- ИРН АР 19677271
- Keywords
- bacterial translocation, presepsin, intraabdominal hypertension, multi-organ disorder, I-FABP, REG3a, Zonulin
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Karaganda Medical UniversityUniversity, hospital or other
- Study start
- 1 Mar 2023 (actual)
- Primary completion
- 25 Dec 2025 (estimated)
- Study completion
- 27 Dec 2025 (estimated)
- First posted
- 24 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Main scientific hypotheses of the project:
- The level of intestinal microflora translocation markers and biomarkers of intestinal wall damage the in the blood serum correlates with the level of intra-abdominal pressure, regardless of the genesis of intra-abdominal hypertension.
- The critical levels of intestinal microflora translocation markers and biomarkers of the intestinal wall damage can be used for predicting an unfavorable outcome in the multiple organ dysfunction syndrome.
- The revealed critical level of intra-abdominal pressure is an additional prognostic sign in assessing the course of the multiple organ dysfunction syndrome.
. Project objectives:
- To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.
- To identify differences in the level of markers of bacterial translocation of the intestinal microflora and the level of markers of the intestinal wall damage in patients with intra-abdominal hypertension. In patients with multiple organ dysfunction syndrome, the levels of biomarkers of bacterial translocation of the intestinal microflora and biomarkers of intestinal wall damage in the blood serum correlate with intra-abdominal pressure indicators, regardless of the etiology of intra-abdominal hypertension.
- Assess the impact of the level of intra-abdominal pressure on the development and course of the syndrome of multiple organ dysfunction. To assess the course of the syndrome of multiple organ dysfunction, an additional prognostic marker is the determination of the critical level of intra-abdominal pressure.
- Determine the critical levels of biomarkers of intestinal microflora translocation and biomarkers of intestinal wall damage to predict the outcome of diseases accompanied by the development of multiple organ dysfunction syndrome. The obtained critical levels of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage will be significant indicators in the syndrome of multiple organ dysfunction for predicting an unfavorable outcome.
Detailed description
The aim of the project is to evaluate the impact of intra-abdominal hypertension, biomarkers of bacterial translocation and biomarkers of intestinal wall damage on the course and outcomes of the disease in patients with multiple organ dysfunction.
Today the intestinal microflora translocation is considered as one of the key mechanism of an enhanced systemic inflammatory response that leads to multiple organ dysfunction. In the intensive care unit, in patients in serious condition changes in various body systems develop, including the immune system reacts with the production of endogenous pro-inflammatory mediators, and due to microcirculation disorders, ischemia and hypoxia of the intestinal wall, aggravated by an increase in intra-abdominal pressure, its permeability increases, its barrier function is impaired. As a result, bacteria and/or their endotoxins penetrate the damaged intestinal barrier and further enhance the immune response, which becomes systemic and ultimately leads to multiple organ dysfunction. When the described processes occur, the assessment of splanchnic blood flow becomes especially relevant.
sCD14-ST (presepsin) and LBP (lipopolysaccharide-binding protein) are being studied as biomarkers of bacterial translocation, and I-FABP (Intestinal fatty-acid binding protein), REG3α (regenerating islet-derived protein-3α) and Zonulin (zonulin) are being studied as biomarkers of intestinal wall injury.
The interaction of the macrophage membrane protein CD14 with peptidoglycans of gram-positive and lipopolysaccharides of the walls of gram-negative bacteria leads to the production of sCD14-ST. Presepsin is a biomarker for the early phase of sepsis and a predictor of outcome in septic patients.
LBP increases the sensitization of receptors of cells of the immune system: macrophages, monocytes, neutrophils to bacterial lipopolysaccharide, which leads to the activation of the immune response by releasing pro-inflammatory mediators. LBP appears to be an effective biomarker for bacterial translocation and the development of septic complications.
I-FABP is a protein that is located on the villi of mature enterocytes. An increase in the level of I-FABP in the blood serum is associated with a violation of the permeability of the intestinal wall, which has been proven in a number of studies.
Paneth cells secrete the antimicrobial protein REG3α into the intestine, and in case of the intestinal wall damage, it moves into the bloodstream. This protein is a reliable biomarker of intestinal wall damage.
Zonulin is a protein that playing a significant role in intestinal wall permeability. It opens the intracellular tight junctions between the cells of the duodenum and small intestine, which leads to an increase in the permeability of the intestinal wall. Therefore, serum zonulin is a marker of dysfunction and increased permeability of the intestinal barrier.
In the databases of publications (Scopus, Web of Science) there were no articles on the study of the relationship between the level of biomarkers of intestinal translocation, the level of biomarkers of the intestinal wall damage and the level of intra-abdominal pressure in patients with multiple organ dysfunction syndrome. This study will allow a more in-depth study of the pathogenesis of intestinal microflora translocation in patients with multiple organ dysfunction syndrome, and will also allow using the results obtained to predict the course of this condition.
Detection of blood serum biomarkers sCD14-ST, LBP, I-FABP, REG3α and Zonulin will be performed by enzyme immunoassay. The level of intra-abdominal pressure will be measured by the method of tonometry in the bladder through a urethral catheter using a portable invasive low pressure meter (IIND - 500/75) by Triton-Electronics LLC.
The expected scientific results of studying the relationship between intra-abdominal pressure, the phenomenon of translocation of intestinal microflora into the systemic circulation with the pathogenesis and dynamics of the development of multiple organ dysfunction syndrome will have an impact on the further improvement of the treatment tactics of this pathology. Innovative methods for diagnosing the phenomenon of intestinal microflora translocation will have a positive effect on the development of laboratory diagnostics and science in Kazakhstan.
Revealing of relationships between intestinal microflora translocation biomarkers, biomarkers of the intestinal wall damage and changes in intra-abdominal pressure will allow a more in-depth study of the pathogenetic mechanisms in the development and course of the multiple organ dysfunction syndrome, depending on its genesis, which will allow using the results obtained to predict the outcomes of this syndrome.
2.2. The aim of the project is to evaluate the impact of intra-abdominal hypertension, biomarkers of bacterial translocation, and biomarkers of the intestinal wall damage on the course and outcomes of the disease in patients with multiple organ dysfunction.
2.3. Project objectives:
- To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.
- To identify differences in the level of markers of bacterial translocation of the intestinal microflora and the level of markers of the intestinal wall damage in patients with intra-abdominal hypertension. In patients with multiple organ dysfunction syndrome, the levels of biomarkers of bacterial translocation of the intestinal microflora and biomarkers of intestinal wall damage in the blood serum correlate with intra-abdominal pressure indicators, regardless of the etiology of intra-abdominal hypertension.
- Assess the impact of the level of intra-abdominal pressure on the development and course of the syndrome of multiple organ dysfunction. To assess the course of the syndrome of multiple organ dysfunction, an additional prognostic marker is the determination of the critical level of intra-abdominal pressure.
- Determine the critical levels of biomarkers of intestinal microflora translocation and biomarkers of intestinal wall damage to predict the outcome of diseases accompanied by the development of multiple organ dysfunction syndrome. The obtained critical levels of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage will be significant indicators in the syndrome of multiple organ dysfunction for predicting an unfavorable outcome.
- Scientific novelty and significance of the project Multiple Organ Dysfunction Syndrome (MODS) is a potentially reversible physiological disorder involving two or more organ systems not involved in the process resulting in intensive care unit (ICU) hospitalization. MODS results in longer ICU stays and, in severe cases, leads to high mortality (27%-100%).
In this scientific project, it is planned to study the levels of biomarkers of bacterial translocation (sCD14-ST, LBP) levels of biomarkers of intestinal wall damage (I-FABP, REG3α and Zonulin) and intra-abdominal pressure in patients with multiple organ dysfunction syndrome.
The interaction of the macrophage membrane protein CD14 with peptidoglycans of gram-positive and lipopolysaccharides of the walls of gram-negative bacteria leads to the production of sCD14-ST . Presepsin is a biomarker for the early phase of sepsis and a predictor of outcome in septic patients.
LBP increases the sensitization of receptors of cells of the immune system: macrophages, monocytes, neutrophils to bacterial lipopolysaccharide, which leads to the activation of the immune response by releasing pro-inflammatory mediators. LBP appears to be an effective biomarker for bacterial translocation and the development of septic complications.
I-FABP is a protein that is located on the villi of mature enterocytes. An increase in the level of I-FABP in the blood serum is associated with a violation of the permeability of the intestinal wall, which has been proven in a number of studies.
Paneth cells secrete the antimicrobial protein REG3α into the intestine, and in case of the intestinal wall damage, it moves into the bloodstream. This protein is a reliable biomarker of intestinal wall damage and bacterial translocation.
Zonulin first described like it is a protein that playing a significant role in intestinal wall permeability. It opens the intracellular tight junctions between the cells of the duodenum and small intestine, which leads to an increase in the permeability of the intestinal wall. Therefore, serum zonulin is a marker of dysfunction and increased permeability of the intestinal barrier.
- Research methods The type of research being conducted is fundamental research. The design of the study complies with the principles of the Declaration of Helsinki of the World Medical Association and was approved by the Local Commission on Bioethics of the NJSC KMU. Clinical bases in Karaganda, where biological material will be taken: Multidisciplinary Hospital No. 1, Regional Clinical Hospital, Clinic of Medical University. Laboratory research will be carried out on the basis of the Research Laboratory of the Institute of Life Sciences of the NJSC KMU.
Main scientific hypotheses of the project:
- The level of intestinal microflora translocation markers and biomarkers of intestinal wall damage the in the blood serum correlates with the level of intra-abdominal pressure, regardless of the genesis of intra-abdominal hypertension.
- The critical levels of intestinal microflora translocation markers and biomarkers of the intestinal wall damage can be used for predicting an unfavorable outcome in the multiple organ dysfunction syndrome.
- The revealed critical level of intra-abdominal pressure is an additional prognostic sign in assessing the course of the multiple organ dysfunction syndrome.
Research material. It is planned to study bacterial translocation biomarkers (sCD14-ST, LBP), biomarkers of intestinal wall damage (I-FABP, REG3α and Zonulin) in blood serum and measure intra-abdominal pressure in 180 patients with multiple organ dysfunction syndrome.
Measurement of intra-abdominal pressure will be carried out in patients with multiple organ dysfunction syndrome through a urethral catheter using a portable electronic device "ILPM - 500/75" (invasive low-pressure meter) manufactured by LLC "Triton - ElectronicS", Yekaterinburg, RF.
Technique for measuring intra-abdominal pressure: 50 ml of warm sterile isotonic sodium chloride solution is injected into the previously emptied bladder through a Foley catheter with an inflated balloon using a syringe without a needle. The urethral catheter is attached to the measuring device. With the valve of the urethral catheter closed, a zero value is set, after which the valve of the catheter is opened and the intra-abdominal pressure is recorded according to the indication on the display of the device
Risks and their solutions:
- With an increase in prices for the necessary reagents and materials due to the constant change in the exchange rate, most of the purchase will be carried out in the 1st year of the project implementation. Reducing the number of studies conducted while maintaining statistical significance without significant losses for the project.
- When changing the place and dates of congresses and conferences with a change in travel costs, there will be changes in the number of business travelers.
Study design
- Observational model
- Case crossover
- Time perspective
- Prospective
- Target follow-up
- 10 Days
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 | – | Diagnostic Test: immunoenzyme analysisthe first group consists of patients with increased abdominal pressure, signs of multi-organ failure with a fatal outcome |
| Group 2 | – | Diagnostic Test: immunoenzyme analysisthe second group consists of patients with increased abdominal pressure, signs of multi-organ failure without death |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients over 18 years of age with multi-organ dysfunction syndrome and increased intra-abdominal pressure
Key inclusion criteria (2 listed)
- registered multiple organ dysfunction syndrome of various genesis
- over 18 years of age.
Key exclusion criteria (3 listed)
- age under 18
- pregnancy
- HIV infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| immunoenzyme analysisimmunoenzyme analysis with EVOLIS system | Diagnostic test | Group 1, Group 2 |
Primary outcome
Detection of biomarkers of translocation
Time frame: 3-10 days
To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.
1 secondary outcome
The differences between level of bacterial translocation and level of markers of the intestinal wall damage with intraabdominal hypertension
Time frame: 3-10 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Apr 2024.
- Results publication: PubMed 34729040Turgunov Y, Ogizbayeva A, Akhmaltdinova L, Shakeyev K. Lipopolysaccharide-binding protein as a risk factor for development of infectious and inflammatory postsurgical complications in colorectal cancer paients. Contemp Oncol (Pozn). 2021;25(3):198-203. doi: 10.5114/wo.2021.110051. Epub 2021 Oct 14.
- Results publication: PubMed 35368178Shakeyev K, Turgunov Y, Ogizbayeva A, Avdiyenko O, Mugazov M, Grigolashvili S, Azizov I. Presepsin (soluble CD14 subtype) as a risk factor for the development of infectious and inflammatory complications in operated colorectal cancer patients. Ann Coloproctol. 2022 Dec;38(6):442-448. doi: 10.3393/ac.2022.00115.0016. Epub 2022 Apr 4.
- Results publication: PubMed 31625067Amanova DY, Lavrinenko AV, Kaliyeva DK, Matyushko DN, Ivachyov PA, Turgunov YM. Comparative Evaluation of Translocation of GFP Producing Escherichia coli Strains in Acute Intestinal Obstruction. Bull Exp Biol Med. 2019 Sep;167(5):660-662. doi: 10.1007/s10517-019-04593-y. Epub 2019 Oct 17.
- Results publication: PubMed 32841201Ivachyov P, Amanova D, Akhmaltdinova L, Koishibayev Z, Turgunov E. [COMPARISON OF DYNAMICS OF LEVEL OF PROCALCITONIN, LIPOPOLYSACCHARIDE BINDING PROTEIN AND INTERLEUKIN-6 IN BLOOD SERUM OF EXPERIMENTAL ANIMALS AT STRANGULATED AND OBTURATIVE INTESTINAL OBSTRUCTION]. Georgian Med News. 2020 Jun;(303):173-177. Russian.
- Annals of Coloproctology 2022;38(6):442-448Link provided by the sponsor.
- J CLIN MED KAZ, Volume 18, Issue 3, pp. 8-13.Link provided by the sponsor.
- J CLIN MED KAZ, Volume 19, Issue 2, pp. 38-42.Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Intraabdominal Hypertension
Enrolling by invitationObservational study
WSACS 2026 Delphi Consensus on the Practical Management of Intra-abdominal Hypertension and Abdominal Compartment Syndrome
Intra-Abdominal Hypertension, Abdominal Compartment Syndrome
Not yet recruitingObservational study
From Blast Injury to Multicompartment Dysfunction:
Compartment Syndrome, Compartment Syndrome Nontraumatic Lower Extremity
Recruiting
Low Pneumoperitoneum Pressure for Delirium Prevention in Elderly Laparoscopy
Postoperative Delirium (POD), Intracranial Hypertension
Not yet recruitingObservational study
Intra-Abdominal Pressure, Respiratory Mechanics, and Ventilator Liberation After Emergency Major Laparotomy
Intra-Abdominal Hypertension, Respiratory Mechanics
Not yet recruitingObservational study
Cumulative Intra-Abdominal Pressure Burden and Acute Kidney Injury After Emergency Abdominal Surgery
Acute Kidney Injury, Intra-Abdominal Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alina Ogizbaeva, dr principal investigator
young scientist, phD
Kairat Shakeyev, dr principal investigator
head of the surgical service of the CSE "Multidisciplinary Hospital No. 3 of Karaganda
Dmitry Matyushko, dr principal investigator
PhD, Associate Professor of the Department of Surgical Diseases
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intraabdominal Hypertension and Multi-Organ Disorder, run by Karaganda Medical University at 5 sites in Kazakhstan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection of biomarkers of translocation (time frame: 3-10 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06221293, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024.